يعرض 1,681 - 1,700 نتائج من 4,380 نتيجة بحث عن 'significantly ((((((teer decrease) OR (greater decrease))) OR (mean decrease))) OR (nn decrease))', وقت الاستعلام: 0.62s تنقيح النتائج
  1. 1681
  2. 1682

    a, Anti-correlation of gene expression between <i>dmdR1</i> and its predicted regulon. Left: Pearson correlation coefficients (PCCs) between <i>dmdR1</i> and all genes with a DmdR1 position weight matrix (PWM) score greater than 15 in their regulatory region. The vertical dashed line marks the refined PWM score threshold of 22.875.... حسب Hannah E. Augustijn (10773096)

    منشور في 2025
    "…Left: Pearson correlation coefficients (PCCs) between <i>dmdR1</i> and all genes with a DmdR1 position weight matrix (PWM) score greater than 15 in their regulatory region. The vertical dashed line marks the refined PWM score threshold of 22.875. …"
  3. 1683

    Summary of study eligibility criteria. حسب Biban Gill (1473337)

    منشور في 2025
    "…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …"
  4. 1684

    Summary of study participation and feasibility. حسب Biban Gill (1473337)

    منشور في 2025
    "…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …"
  5. 1685
  6. 1686
  7. 1687
  8. 1688
  9. 1689
  10. 1690
  11. 1691
  12. 1692
  13. 1693
  14. 1694
  15. 1695
  16. 1696
  17. 1697
  18. 1698
  19. 1699
  20. 1700